CA2873771A1 - Ledgf peptides and formulations thereof for treatment of degenerative disorders - Google Patents

Ledgf peptides and formulations thereof for treatment of degenerative disorders Download PDF

Info

Publication number
CA2873771A1
CA2873771A1 CA2873771A CA2873771A CA2873771A1 CA 2873771 A1 CA2873771 A1 CA 2873771A1 CA 2873771 A CA2873771 A CA 2873771A CA 2873771 A CA2873771 A CA 2873771A CA 2873771 A1 CA2873771 A1 CA 2873771A1
Authority
CA
Canada
Prior art keywords
ledgf1
disease
composition
peptide
ledgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873771A
Other languages
English (en)
French (fr)
Inventor
Uday B. Kompella
Rinku BAID
Arun K. Upadhyay
Sarath YANDRAPU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of CA2873771A1 publication Critical patent/CA2873771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
CA2873771A 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders Abandoned CA2873771A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
US61/649,847 2012-05-21
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
USPCT/US2012/065620 2012-11-16
PCT/US2013/042074 WO2013177198A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Publications (1)

Publication Number Publication Date
CA2873771A1 true CA2873771A1 (en) 2013-11-28

Family

ID=49624295

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873771A Abandoned CA2873771A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Country Status (12)

Country Link
US (2) US9526760B2 (enExample)
EP (1) EP2852399B1 (enExample)
JP (2) JP6632376B2 (enExample)
CN (2) CN110054677A (enExample)
AU (1) AU2013266468B2 (enExample)
BR (1) BR112014028951A8 (enExample)
CA (1) CA2873771A1 (enExample)
DK (1) DK2852399T3 (enExample)
ES (1) ES2791251T3 (enExample)
IN (1) IN2014MN02461A (enExample)
RU (1) RU2617964C2 (enExample)
WO (1) WO2013177198A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177198A1 (en) * 2012-05-21 2013-11-28 The Regents Of The University Of Colorado, A Body Corporate Ledgf peptides and formulations thereof for treatment of degenerative disorders
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
EP3880233A1 (en) 2018-06-22 2021-09-22 Bioralix B.V. Formulations of biological polymers for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1562627A4 (en) 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
US7514233B2 (en) 2002-09-26 2009-04-07 K.U. Leuven Research & Development Integrase cofactor
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005118869A2 (en) * 2004-05-28 2005-12-15 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
ES2406716T3 (es) 2005-12-30 2013-06-07 Neurotech Usa, Inc. Dispositivo micronizado para el suministro de moléculas activas biológicamente y método de uso del mismo
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008053478A2 (en) * 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008103265A2 (en) * 2007-02-16 2008-08-28 The Brigham And Women's Hospital, Inc. Methods of using ledgf/p75
WO2009155936A1 (en) * 2008-06-26 2009-12-30 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2726867B1 (en) * 2011-07-01 2016-04-06 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
WO2013177198A1 (en) * 2012-05-21 2013-11-28 The Regents Of The University Of Colorado, A Body Corporate Ledgf peptides and formulations thereof for treatment of degenerative disorders

Also Published As

Publication number Publication date
EP2852399A1 (en) 2015-04-01
RU2617964C2 (ru) 2017-04-28
WO2013177198A1 (en) 2013-11-28
IN2014MN02461A (enExample) 2015-07-10
JP2018172386A (ja) 2018-11-08
EP2852399B1 (en) 2020-02-19
US20170129929A1 (en) 2017-05-11
AU2013266468B2 (en) 2017-11-09
JP6632376B2 (ja) 2020-01-22
EP2852399A4 (en) 2016-03-23
CN110054677A (zh) 2019-07-26
US9526760B2 (en) 2016-12-27
RU2014151603A (ru) 2016-07-10
US20150147404A1 (en) 2015-05-28
BR112014028951A8 (pt) 2021-09-14
AU2013266468A1 (en) 2014-12-18
CN104470534A (zh) 2015-03-25
BR112014028951A2 (pt) 2017-07-25
JP2015519343A (ja) 2015-07-09
ES2791251T3 (es) 2020-11-03
US10221226B2 (en) 2019-03-05
DK2852399T3 (da) 2020-05-04

Similar Documents

Publication Publication Date Title
US9102763B2 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
JP6585720B2 (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
US10221226B2 (en) LEDGF peptides and formulations thereof for treatment of degenerative disorders
AU2016241499B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EP3424948A1 (en) Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis
JP6884755B2 (ja) ペプチド組成物および使用方法
EP2968471A1 (en) Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
WO2023151600A1 (en) Methods for treating cataracts using polypeptides
JP6744862B2 (ja) 眼疾患を治療するためのシリビニンおよび他の有効成分を送達するためのナノ構造製剤
WO2012135575A2 (en) Compositions and methods for introduction of macromolecules into cells
EP4197558A1 (en) Composition of drug and wild-type cell-penetrating peptide derivative
US20120184498A1 (en) Dermaseptin b2 used as an inhibitor of the growth of a tumor
CN105017406B (zh) 一类新的具有神经保护功能的多肽
Nan et al. Cell-penetrating peptide Penetratin-modified liposomes for ophthalmic application: construction and in vitro evaluation
HK40073385A (en) Methods for treating cataracts using polypeptides
TW202415387A (zh) 用於治療眼科疾患之持續釋放二氧化矽水凝膠複合物及其使用方法
HK40087448A (en) Composition of drug and wild-type cell-penetrating peptide derivative
HK40091461A (zh) 使用多肽治疗白内障的方法
Tang et al. Enhancing the Ability of Proteins to Pass Through Corneal Biobarriers by Decorating Hexahistidine-Metal Assemblies with Tyrosine
Delgado et al. DEXTRAN-PROTAMINE-SOLID LIPID NANOPARTICLES AS POTENTIAL VECTORS FOR THE TREATMENT OF X LINKED JUVENILE RETINOSCHISIS.
Baid Lens epithelium derived growth factor (1-326): a new protein drug for retinal diseases
Jian-xing The potential of nanomedicine therapies to treat neovascular disease in the retina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180508

FZDE Discontinued

Effective date: 20210831